These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27633490)

  • 1. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
    de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
    Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
    J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
    Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
    Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
    Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
    Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
    Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
    Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
    Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
    Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
    Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
    Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
    Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
    Oncology; 1999; 56(4):338-44. PubMed ID: 10343200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
    Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
    J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
    Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
    Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
    Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
    Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of multiple serum markers in advanced melanoma.
    Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
    Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
    Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
    J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.
    Gebhardt C; Lichtenberger R; Utikal J
    J Dtsch Dermatol Ges; 2016 Feb; 14(2):158-64. PubMed ID: 26819111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients.
    Panasiti V; Curzio M; Roberti V; Lieto P; Devirgiliis V; Gobbi S; Naspi A; Coppola R; Lopez T; di Meo N; Gatti A; Trevisan G; Londei P; Calvieri S
    Dermatology; 2013; 227(1):55-61. PubMed ID: 24008289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.